Plasma cell-free RNA PD-L1 expression and survival with immune checkpoint inhibitor-based treatment in advanced non-small-cell lung cancer

被引：0
|
作者：
Walker, Paul R. [1 ]
Jayananda, Sriraksha [1 ]
Pasli, Melisa [1 ]
Muzaffar, Mahvish [1 ]
机构：
[1] East Carolina Univ, Brody Sch Med, Greenville, NC 27858 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21090
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer
    Sakamoto, Mandy
    Jimeno, Antonio
    DRUGS OF TODAY, 2023, 59 (03) : 169 - 177
  • [32] Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors
    Barlesi, Fabrice
    Tomasini, Pascale
    LANCET ONCOLOGY, 2020, 21 (05): : 607 - 608
  • [33] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    D'Incecco, A.
    Andreozzi, M.
    Ludovini, V.
    Rossi, E.
    Capodanno, A.
    Landi, L.
    Tibaldi, C.
    Minuti, G.
    Salvini, J.
    Coppi, E.
    Chella, A.
    Fontanini, G.
    Filice, M. E.
    Tornillo, L.
    Incensati, R. M.
    Sani, S.
    Crino, L.
    Terracciano, L.
    Cappuzzo, F.
    BRITISH JOURNAL OF CANCER, 2015, 112 (01) : 95 - 102
  • [34] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    A D'Incecco
    M Andreozzi
    V Ludovini
    E Rossi
    A Capodanno
    L Landi
    C Tibaldi
    G Minuti
    J Salvini
    E Coppi
    A Chella
    G Fontanini
    M E Filice
    L Tornillo
    R M Incensati
    S Sani
    L Crinò
    L Terracciano
    F Cappuzzo
    British Journal of Cancer, 2015, 112 : 95 - 102
  • [35] Plasma cell free PD-L1 RNA expression correlated with tissue PD-L1 immunohistochemical staining and tumor mutation burden in non-small cell lung cancer.
    Walker, Paul R.
    Bowling, Mark
    Sharma, Nitika
    Namireddy, Praveen
    Parent, Teresa
    Cherry, Cynthia R.
    Yeh, Chen-Hsiung
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
    Cabezon-Gutierrez, Luis
    Custodio-Cabello, Sara
    Palka-Kotlowska, Magda
    Alonso-Viteri, Soledad
    Khosravi-Shahi, Parham
    CLINICAL LUNG CANCER, 2021, 22 (05) : 381 - 389
  • [37] Reliability of Small Biopsy Samples for Tumor PD-L1 Expression in Non-Small-Cell Lung Cancer
    Tsunoda, A.
    Morikawa, K.
    Okamoto, M.
    Inoue, T.
    Kida, H.
    Furuya, N.
    Handa, H.
    Nishine, H.
    Inoue, T.
    Miyazawa, T.
    Mineshita, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2125 - S2125
  • [38] PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer
    Gureviciene, Giedre
    Matulione, Jurgita
    Poskiene, Lina
    Miliauskas, Skaidrius
    Zemaitis, Marius
    MEDICINA-LITHUANIA, 2024, 60 (03):
  • [39] First-Line Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer (NSCLC) - A Network Meta-Analysis by PD-L1
    San Tan, P.
    Nazareth Aguiar Junior, P.
    Husnain, M.
    Haaland, B.
    Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S467 - S467
  • [40] PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes
    Miyazawa, Tomoyuki
    Marushima, Hideki
    Saji, Hisashi
    Kojima, Koji
    Hoshikawa, Masahiro
    Takagi, Masayuki
    Nakamura, Haruhiko
    ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 25 (01) : 1 - 9
12345